Back to All Combinations

RET Fusion

Intermediate Prognosis
0.20% Prevalence Level 2A Rare Fusions
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
RET
Treatment Implications

Very rare but highly actionable.

Recommended Treatments
Selpercatinib
Pralsetinib
Treatments to Avoid

No specific contraindications noted

Study References

LIBRETTO-001, ARROW

Key Statistics
0.20%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Identify through comprehensive NGS.
Information

Category: Rare Fusions

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.